Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative.
暂无分享,去创建一个
W. Gibler | E. Ohman | E. Peterson | R. Becker | M. Roe | Tracy Y. Wang | A. Chen
[1] E. Topol,et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.
[2] Carl J Pepine,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.
[3] E. Topol,et al. Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade. , 2000, The American journal of cardiology.
[4] Salim Yusuf,et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.
[5] J. Hirsh,et al. Managing oral anticoagulant therapy. , 2001, Chest.
[6] J. Muhlestein,et al. Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy , 2003 .
[7] E W Steyerberg,et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. , 2000, Circulation.
[8] A. Mitchell,et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. , 2002, JAMA.
[9] Clopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation. , 2003, Thrombosis and haemostasis.
[10] J. W. Schaeffer,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary article , 2002 .
[11] K. Eagle,et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. , 2007, JAMA.
[12] W Klein,et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). , 2004, European heart journal.
[13] Carl J Pepine,et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.
[14] Taylor Aj,et al. Can warfarin randomized trials be reproduced in 'real life'? Adherence to warfarin guidelines for intensity of anticoagulation in a university-based warfarin clinic. , 2000 .
[15] T. Doherty,et al. How does warfarin affect the activated coagulation time? , 1998, American heart journal.
[16] K Y Liang,et al. Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.
[17] D. Newman,et al. The prevalence of nontherapeutic and dangerous international normalized ratios among patients receiving warfarin in the emergency department. , 2006, Annals of emergency medicine.